)

Vir Biotechnology (VIR) investor relations material
Vir Biotechnology Q2 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Executive summary
Advanced hepatitis delta and oncology pipelines, with all ECLIPSE registrational studies enrolling and first patient dosed in Phase 1 study of VIR-5525 in July 2025, expanding the oncology pipeline to three ongoing Phase 1 studies.
Strategic realignment and restructuring led to cost savings, including phasing out certain research programs and site closures.
Diversified pipeline includes siRNA, antibody, and masked T-cell engager platforms, with multiple assets in Phase 1–3 trials.
No material legal proceedings or off-balance sheet arrangements reported.
Focus on immune system-based therapies for cancer and infectious diseases, with lead programs in oncology and hepatitis delta.
Financial highlights
Q2 2025 total revenues were $1.2M, down from $3.1M in Q2 2024; net loss for Q2 2025 was $111.0M, compared to $138.4M in Q2 2024.
R&D expenses for Q2 2025 were $97.5M, down from $105.1M in Q2 2024, reflecting restructuring savings.
SG&A expenses for Q2 2025 were $22.3M, down from $30.3M in Q2 2024, due to headcount reductions and restructuring.
Cash, cash equivalents, and investments totaled $892.1M as of June 30, 2025, with restricted cash of $95.2M.
Net cash consumed in Q2 2025 was $127.7M, including $50.5M in milestone payments; excluding these, net cash consumed was $77.2M.
Outlook and guidance
Cash runway projected into mid-2027, supporting advancement of key programs through value inflection points.
Focused on driving ECLIPSE study enrollment, advancing T cell engager programs, and executing business development strategies.
Anticipates providing 48-week Solstice study data by year-end and meaningful updates on T cell engager programs as data mature.
No significant revenue expected from sotrovimab or other product sales until regulatory approvals are obtained.
Multiple clinical catalysts anticipated, including pivotal HDV studies and Phase 1 oncology data.
Next Vir Biotechnology earnings date

Next Vir Biotechnology earnings date

The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
)
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
)
I can't remember the last time an app had such a positive impact on my investment process.
)
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
)
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
I can't remember the last time an app had such a positive impact on my investment process.
)
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
)
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
)
)
)
Frequently asked questions
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Explore our global coverage